# Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupi vs. Bupi Only Administered as Combined Sciatic and Adductor Canal Nerve Block for Postsurgical Analgesia in Lower Extremity Surgeries

> **NCT03954639** · PHASE3 · WITHDRAWN · sponsor: **Pacira Pharmaceuticals, Inc**

## Conditions studied

- Bunion
- Metatarsophalangeal Fusion
- Midfoot Fusion
- Hindfoot Fusion
- Total Ankle Arthroplasty
- Forefoot Surgery

## Interventions

- **DRUG:** EXPAREL 13.3Mg/mL Suspension for Injection
- **DRUG:** Bupivacaine Hydrochloride

## Key facts

- **NCT ID:** NCT03954639
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-15
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision.
- **Last updated:** 2020-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03954639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03954639, "Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupi vs. Bupi Only Administered as Combined Sciatic and Adductor Canal Nerve Block for Postsurgical Analgesia in Lower Extremity Surgeries". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03954639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*